FDA
-
-
-
-
-
-
-
Travere licenses BTK inhibitor from Everest for rare kidney diseases
-
-
-
-
-
-
-
FDA approves FILSPARI for rare kidney disease FSGS
-
-
-
-
-
-
-
Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
FDA;s messaging is positive for Travere Therapeutics (TVTX) - Cantor Fitzgerald
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $47 at H.C. Wainwright
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
-
328,337 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

